Related Experiment Video
Updated: Nov 3, 2025
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations
Laura Dresser1, Richard Wlodarski1, Kourosh Rezania1
1Department of Neurology, University of Chicago, Chicago, IL 60637, USA.
Abstract:
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 cases per million. MG is considered a classic example of antibody-mediated autoimmune disease. Most patients with MG have autoantibodies against the acetylcholine receptors (AChRs). Less commonly identified autoantibodies include those targeted to muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (Lrp4), and agrin. These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane. The core clinical manifestation of MG is fatigable muscle weakness, which may affect ocular, bulbar, respiratory and limb muscles. Clinical manifestations vary according to the type of autoantibody, and whether a thymoma is present.
Insights
Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions. Autoantibodies against acetylcholine receptors (AChRs) or other targets cause muscle weakness, impacting various muscle groups.
Area of Science:
- Neurology
- Immunology
- Autoimmune Diseases
Background:
- Myasthenia gravis (MG) is an autoimmune neurological disorder impacting neuromuscular junction transmission.
- It affects 150-200 individuals per million, presenting as fatigable muscle weakness.
- MG is a prime example of antibody-mediated autoimmune disease.
Purpose of the Study:
- To summarize the pathophysiology and clinical manifestations of myasthenia gravis.
- To highlight the role of autoantibodies in MG pathogenesis.
- To describe the spectrum of clinical presentations based on autoantibody type and thymoma presence.
Main Methods:
- Literature review of autoimmune neurological disorders.
- Analysis of epidemiological data for MG incidence and prevalence.
- Review of immunological mechanisms in neuromuscular transmission defects.
Main Results:
- Autoantibodies against acetylcholine receptors (AChRs) are common in MG.
- Antibodies to MuSK, Lrp4, and agrin are less frequent but significant.
- These antibodies disrupt AChR function and clustering, leading to muscle weakness.
Conclusions:
- MG is characterized by autoantibodies disrupting neuromuscular transmission.
- Clinical presentation varies with autoantibody type and thymoma status.
- Understanding these mechanisms is crucial for diagnosing and managing MG.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:27Myocarditis II: Clinical Features and Diagnostic Tests